Susan Orr, OD

Dr. Orr has broad experience and expertise in eye care, driven largely by intellectual curiosity and a desire to help patients. Following 10 years private practice in Canada, Dr. Orr joined Alcon in roles of increasing responsibility across international clinical development, pharmacology, business development and licensing, pipeline/product strategy, and marketing. Moving to Janssen, Dr. Orr developed the therapeutic strategy for Janssen’s nascent retina team. Moving from large pharma to start-up, Dr. Orr took on the role of CMO at Notal Vision, an OCT diagnostic company, ultimately advancing to CEO.
Dr. Orr joined Clarke Atwell at Claris Biotherapeutics in 2020, enticed by the robust preclinical data and wealth of knowledge surrounding the molecular pathway of their lead dHGF program. Dr. Orr is also a member of the Retinal Global Board of Directors.